RespiGam immune globulin data

Results published in the New England Journal of Medicine showed that the high dose of 750 mg/kg tested in a Phase IIIb/IV trial cut hospital stays by 63 percent from 128 days in the control group to 43 days in the high dose group (p =0.02) and reduced the number of days spent in intensive care (p =0.5).

The drug was given monthly during the RSV season (November to April) to 81 children at the high dose and to 79 children at the lower dose tested, 150 mg/kg. As compared to the 89 children in the control group, incidence of moderate or severe disease was reduced after the high dose by 62 percent (p = 0.01) , and use of the only available treatment, aerosolized ribovarin was also cut (p = 0.05). ...